Pernix Inks $101M Deal To Purchase Cypress Pharmaceuticals
Pediatric pharmaceutical company Pernix Therapeutics Holdings will purchase generic-drug maker Cypress Pharmaceuticals Inc. and its branded subsidiary Hawthorn Pharmaceuticals Inc. in a $101 million deal that will significantly increase its drug...To view the full article, register now.
Already a subscriber? Click here to view full article